- 4.9k views
Anticoagulants in CVD
The financial burden of thrombotic events in cardiovascular disease is enormous. Anticoagulant medication is advised for the treatment and secondary prevention of acute coronary syndrome as well as the prevention of thrombotic events in numerous cardiovascular disorders, such as stroke in atrial fibrillation. Present-day parenteral anticoagulants consist of fondaparinux, low-molecular-weight heparins (LMWHs), and unfractionated heparin. When admitted to the hospital, patients with acute coronary syndrome are typically given either unfractionated heparin or a low-molecular weight heparin (LMWH). Both treatments are equally effective in lowering the risk of death and myocardial infarction, although LMWHs may be safer and don't need to be monitored for blood clotting. Using fondaparinux reduces mortality from acute coronary syndrome considerably when compared to LMWHs or unfractionated heparin. However, long-term outpatient usage of parenteral medications is inconvenient. The only oral anticoagulants available at this time are vitamin K antagonists. A large unmet need exists for new convenient and well-tolerated oral anticoagulants that do not require routine monitoring.
About the Speaker
Dr. Abhishek Tiwari
Consultant Interventional Cardiologist, Ahalia Hospital, Coimbatore
Dr. Abhishek Tiwari, Consultant Interventional Cardiologist, Ahalia Hospital, Coimbatore
Upcoming Case Discussions
New Approach of treatment of Diabetic Neuropathy
Emerging treatments for diabetic neuropathy focus on addressing the root causes and providing symptomatic relief. Novel therapies include advanced pain management drugs, nerve regeneration techniques, and the use of antioxidants like alpha-lipoic acid. Regenerative medicine approaches, such as stem cell therapy, aim to repair damaged nerves. Personalized treatment plans incorporating lifestyle changes, glycemic control, and physical therapy are gaining importance. These innovative strategies improve quality of life and target long-term nerve health in diabetic patients.
Alpha Lipoic Acid in Oxidative Stress
Alpha-lipoic acid (ALA) is a potent antioxidant that helps combat oxidative stress by neutralizing free radicals. It regenerates other antioxidants like vitamin C and E, enhancing overall antioxidant defense. ALA plays a crucial role in reducing cellular damage caused by conditions like diabetes, neuropathy, and aging. Its ability to function in both water- and fat-soluble environments makes it versatile in protecting various tissues. Regular supplementation of ALA may improve mitochondrial function and reduce inflammation associated with oxidative stress.
Liver Failure: Causes, Diagnosis, and Management
Liver failure can result from various causes, including chronic liver diseases like cirrhosis, viral hepatitis, or acute conditions such as drug toxicity, and is characterized by a significant decline in liver function. Diagnosis involves clinical evaluation, liver function tests, imaging, and sometimes biopsy, while management focuses on addressing the underlying cause, supportive care, and, in severe cases, liver transplantation.
AI in Public Health
Artificial Intelligence (AI) is revolutionizing public health by enhancing disease surveillance, predicting outbreaks, and optimizing resource allocation. By analyzing vast datasets, AI can identify patterns and provide insights for timely interventions, improving population health outcomes. It aids in personalized healthcare by tailoring prevention strategies and treatments to individual needs. AI-driven tools, like chatbots and health apps, improve accessibility to health information, empowering communities. Additionally, AI supports research by accelerating data analysis in epidemiology and public health studies. However, ethical considerations and data privacy remain crucial challenges to address in leveraging AI for public health.
ECMO in ARDS Management
Extracorporeal Membrane Oxygenation (ECMO) is a life-saving intervention in managing severe Acute Respiratory Distress Syndrome (ARDS) when conventional therapies fail. It supports gas exchange by providing oxygen and removing carbon dioxide externally, allowing the lungs to rest and heal. ECMO is particularly beneficial in refractory hypoxemia or hypercapnia despite optimal ventilatory settings. Recent advancements, including improved circuit designs and anticoagulation protocols, have enhanced outcomes. However, ECMO use requires a multidisciplinary approach, specialized expertise, and careful patient selection to minimize complications like bleeding or infection. While ECMO doesn't replace ARDS treatments, it serves as a critical bridge to recovery or transplantation.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Abhishek Tiwari's Talks on Assimilate
- 12th -Sep-2024, TIME : 5:00PM TO 6:00 PM
- 0
The financial burden of thrombotic events in cardiovascular disease is enormous. Anticoagulant medication is advised for the treatment and secondary prevention of acute coronary syndrome as well as the prevention of thrombotic events in numerous cardiovascular disorders, such as stroke in atrial fibrillation. Present-day parenteral anticoagulants consist of fondaparinux, low-molecular-weight heparins (LMWHs), and unfractionated heparin. When admitted to the hospital, patients with acute coronary syndrome are typically given either unfractionated heparin or a low-molecular weight heparin (LMWH). Both treatments are equally effective in lowering the risk of death and myocardial infarction, although LMWHs may be safer and don't need to be monitored for blood clotting. Using fondaparinux reduces mortality from acute coronary syndrome considerably when compared to LMWHs or unfractionated heparin. However, long-term outpatient usage of parenteral medications is inconvenient. The only oral anticoagulants available at this time are vitamin K antagonists. A large unmet need exists for new convenient and well-tolerated oral anticoagulants that do not require routine monitoring.